

1 Safe by Design implementation in the nanotechnology industry
2 Araceli Sánchez Jiménez¹, Raquel Puelles², Marta Perez-Fernandez², Paloma Gómez³, Leire
3 Barruetabeña³, Nicklas Raun Jacobsen⁴, Blanca Suarez-Merino⁵, Christian Micheletti⁵, Nicolas
4 Manier⁶, Bénédicte Trouiller⁶, Jose Maria Navas⁷, Judit Kalman⁷, Beatrice Salieri⁸, Roland
5 Hischier⁸, Yordan Handzhiyski⁹, Margarita D. Apostolova⁹, Niels Hadrup⁴, Jacques Bouillard⁶,
6 Yohan Oudart¹⁰, Cesar Merino¹¹, Erika Garcia¹¹, Biase Liguori¹², Stefania Sabella¹³, Jerome
7 Rose¹⁴, Armand Maison¹⁴, Karen S. Galea¹, Sean Kelly¹⁵, Sandra Štěpánková¹⁶, Catherine
8 Mouneyrac¹⁷, Andrew Barrick¹⁷, Amelie Chatel¹⁷, María Dusinska¹⁸, Elise Rundén-Pran¹⁸, Espen
9 Mariussen¹⁸, Christophe Bressot⁶, Olivier Aguerre-Chariol⁶, Neeraj Shandilya¹⁹, Henk Goede¹⁹,
10 Julio Gomez-Cordon³, Sophie Simar²⁰, Fabrice Nesslany²⁰, Keld Alstrup Jensen⁴, Martie van
11 Tongeren²¹, Isabel Rodríguez Llopis³

12 ¹ Institute of Occupational Medicine (IOM), Research Avenue North, Edinburgh, UK

13 ² Avanzare Innovación Tecnológica S.L. Av. Lentiscales, 4-6, 26370 Navarrete, La Rioja, Spain

14 ³ GAIKER Technology Centre, Basque Research and Technology Alliance (BRTA). Parque Tecnológico de
15 Bizkaia, E-48170 Zamudio, Spain

16 ⁴ National Research Centre for the Working Environment (NRCWE), Lersoe Park Alle 105, 2100
17 Copenhagen, Denmark

18 ⁵ TEMAS AG, 8048 Zurich, Switzerland

19 ⁶ Institut national de l'environnement industriel et des risques (INERIS), Verneuil-en-Halatte, 60550
20 France

21 ⁷ Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA) Crta. de la Coruña, km 7,5
22 -28040 Madrid, Spain

23 ⁸ Swiss Federal Laboratories for Materials Science and Technology (Empa), Technology and Society Lab
24 (TSL), Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland

25 ⁹ Roumen Tsanev Institute of Molecular Biology, Bulgarian Academy of Sciences, Acad. G. Bonchev Str.,
26 bl. 21, 1113 Sofia, Bulgaria

27 ¹⁰ Nanomakers, 1 Rue de Clairefontaine, 78 120 Rambouillet, France

28 ¹¹ Grupo Antolin, Ctra. Madrid-Irún, Km. 244.8, 09007 Burgos, Spain

29 ¹² Warrant Hub, S.p.A. Corso Mazzini, 11 42015 Correggio (RE) Italia

30 ¹³ Istituto Italiano di Tecnologia (IIT), Nanoregulatory Platform, Drug Discovery and Development
31 Department, Genova, Italy

32 ¹⁴ CNRS, Aix Marseille Univ, IRD, INRAE, Coll France, CEREGE, Aix-en-Provence, France.

33 ¹⁵ Nanotechnology Industries Association (NIA), Avenue Tervueren 143, 1150 Brussels, Belgium

34 ¹⁶ NanoComposix (NanoTech Partner s.r.o.), Václavské náměstí 66, 110 00 Prague 1, Czech Republic

35 ¹⁷ Laboratoire Mer, Molécules, Santé (MMS, EA 2160); Université Catholique de l'Ouest, Angers F-49000
36 France

37 ¹⁸ NILU-Norwegian Institute for Air Research, Department for Environmental Chemistry, Health Effects
38 Laboratory, Instituttveien 18, 2007 Kjeller, Norway

39 ¹⁹ TNO, Princetonlaan 6, 3584 CB Utrecht, Netherlands

40 ²⁰ Institute Pasteur de Lille, Laboratoire de Toxicologie Génétique, 1 rue du Professeur Calmette, BP 245
41 59019 Lille Cedex - France


42 ²¹ The University of Manchester, Oxford Rd. Manchester, M13 9PL,UK

43 Highlights

- 44 • SbD implementation in real-life industrial case studies in the nanotechnology sector
- 45 • Risk Assessment, Life-cycle Assessment and Socio-Economic Assessment of
- 46 nanomaterials

47

48 Graphical Abstract



49

50 Practical Implementation of Safer by design (SbD). SIA: Safe Innovation Approach

51

Abstract

52
53 The implementation of Safe(r) by Design (SbD) in industrial innovations requires an integrated
54 approach where the human, environmental and economic impact of the SbD measures is
55 evaluated across and throughout the nanomaterial (NM) life cycle. SbD was implemented in
56 six industrial companies where SbD measures were applied to NMs, nano-enabled products
57 (NEP) and NM/NEP manufacturing processes.

58 The approach considers human and environmental risks, functionality of the NM/NEP and
59 costs as early as possible in the innovation process, continuing throughout the innovation
60 progresses. Based on the results of the evaluation, a decision has to be made on whether to
61 continue, stop or re-design the NM/NEP/process or to carry out further tests / obtain further
62 data in cases where the uncertainty of the human and environmental risks is too large.
63 However, SbD can also be implemented at later stages when there is already a prototype
64 product or process available, as demonstrated in some of the cases.

65 The SbD measures implemented in some of the case studies did not result in a viable solution.
66 For example the coating of silicon nanoparticles with amorphous carbon increased the
67 conductivity, the stability and reduced the dustiness of the particles and therefore the risk of
68 explosion and the exposure to workers. However the socioeconomic assessment for their use
69 in lithium-ion batteries for cars, when compared to the used of graphite, showed that the
70 increase in performance did not overcome the higher production costs.

71 This work illustrates the complexities of selecting the most appropriate SbD measures and
72 highlights that SbD cannot be solely based on a hazard and exposure assessment but must
73 include other impacts that any SbD measures may have on sustainability including energy
74 consumption and waste generation as well as all associated monetary costs.

75

76 Keywords: nanomaterials, safe by design, risk assessment, life cycle assessment, nano-enabled
77 products, nanotechnology

78

79 1 Introduction

80 The rapid rate at which novel materials are generated requires an agile process to effectively
81 assess and regulate the risks associated to those materials. The development of materials that
82 are safe to humans and the environment from the beginning of the innovation process offers
83 tremendous advantages in a variety of ways (e.g. lower uncertainty of the risks, higher value
84 increased stakeholder confidence, preparedness for future regulation, etc).

85 While safe by design (SbD) or similar concepts such as green chemistry (Anastas and Warner,
86 2000), prevention through design (Cowley, 2000, NIOSH 2011) and inherently safe(r) (Dir.
87 2006/42/EC, Kletz, 2003) are well defined and have been used for decades in various fields
88 (e.g. occupational health and safety, pharmaceutical industry) there is presently no agreed
89 consensus on what SbD encompasses in the nanotechnology sector. Morose et al. 2009
90 concept design for safer nanotechnology was based on five design principles 1) Size, surface
91 and structure; 2) Alternative materials; 3) Functionalisation, 4) Encapsulation and 5) Quantity
92 reduction) that aim to make safer nano-enabled products. Geraci et al. 2015 reported the
93 views from a discussion on the applicability of principles of "Prevention through Design" (PtD)
94 developed for health and safety (i.e. elimination, substitution, engineering controls,
95 administrative controls and personal protective equipment) for to design safer nanomaterials
96 (NMs), manufacturing processes and nano-enabled products (NEP). The participants agreed
97 that PtD further serves a platform to identify opportunities for a risk-focused dialogue up and
98 down the life cycle.

99 Cobaleda-Siles et al. (2016), in line with Monrose's approach, advocates for to establish SbD
100 selection rules and synthetic approaches that can be used for the reduction of hazard exposure
101 and the reduction of NMs migration and release, taking into consideration all stages of the life
102 cycle of the NEP.

103 In 2017, Hjorth et al. reviewed the current SbD concepts and acknowledged that the way SbD
104 is currently communicated tends to treat safety as an inherent material property when it is not
105 and can lead to unrealistic expectations. The authors concluded that SbD should be considered
106 a starting point rather than an end, meaning that products will still need to progress thorough
107 safety evaluations and regulation.

108 Within the European projects NANoREG and Prosafe (Prosafe, 2017) a new concept was
109 developed where SbD aims at identifying, estimating and reducing uncertainties and risks for
110 humans and the environment along the entire value chain, ideally starting at an early stage of
111 the innovation process (Soeteman-Hernandez et al. 2018, Kraegeloh et al. 2018). This concept
112 advocates that safety should be considered as an integral part of the design process (together
113 with functionality and costs), rather than at a later stage once the process is already well
114 advanced. SbD must thereby also include a life cycle sustainability assessment of the long-term
115 ecological and economic impact (Salieri et al. 2020).

116 This manuscript describes the implementation of the NANoREG and Prosafe concept (referred
117 to as the NanoReg2 concept) in six industrial case studies. The NanoReg2 project built around
118 the challenge of coupling SbD to the regulatory process, to demonstrate new principles and
119 ideas based on data from value chain implementation studies to establish SbD as a
120 fundamental pillar in the validation of a novel manufactured nanomaterials (NMs). The
121 companies applied SbD measures to the NMs they commercialised to reduce the hazard (HIQ-
122 nano, Group Antolin and Nanomakers), to reduce the exposure to workers (Avanzare, Group

123 Antolin, Nanomakers), and to reduce the waste and protect the environment (NanoGap) and
124 to the product to protect consumers (nanoComposix).

125 2 Methods

126 The implementation of SbD was industry-led with the assistance of technical experts in
127 toxicology, exposure and risk assessment. A task force was created who visited the companies
128 and discussed potential case study proposals with them. Companies then, after considering
129 their capabilities and time-scale of the project presented their SbD innovation plan to the task
130 force who, upon further discussion, approved it. The selection criteria considered whether the
131 implementation was focused on SbD and cover at least one of the pillars explained below the
132 innovation plan objectives were achievable and the timescale realistic (within the confines of
133 the overall project timescales). The case studies involved different stages of the innovation
134 chain (1) idea; 2) concept 3) prototype 4) pilot production; 5) market entry) and a variety of
135 NMs (graphene, carbon nanofibers (CNF), dye doped SiO₂, silver nanowires, silver
136 nanoparticles, silicon based NMs.

137 Companies had to achieve one or more of the NanoReg2 SbD pillars:

138 **Pillar 1 : safer materials and products by design:** This refers to identifying less hazardous NMs
139 for humans and the environment and designing NEPs that, under normal and unforeseeable
140 conditions, do not release free NMs (unless that is a requirement for their performance) to the
141 environment and where the NMs can be recycled at the end of life.

142 **Pillar 2: safer use of products:** This consists of evaluating the risks during all uses throughout
143 the product lifecycle in order to optimize defined acceptable uses. Building on the first SbD
144 pillar, when a product has been made as safe as is possible, this second pillar will facilitate an
145 evaluation and determine any potential restrictions on the use of a specific NEP.

146 **Pillar 3: safer industrial production:** This pillar aims to enable a better control on the industrial
147 processes along the production chain. The aim is to design processes that eliminate/reduce
148 release of NMs to the workplace and outdoor environment, do not use hazardous chemicals,
149 reduce NM-waste, do not pose a safety hazard (e.g. explosion) and optimize energy
150 consumption.

151 Before the implementation was started, training on SbD was provided to the six companies in
152 the form of a face-to-face workshop and a technical partner was allocated to each company to
153 advise them during the implementation. Companies were not given a specific protocol, they
154 applied SbD adapting it to their existing decision making processes. Overall the SbD
155 implementation implied the following steps:

156 1) Scenario Identification: identify the pillar(s) that will be the focus of the implementation,
157 the functionality of the NM and the stage of the innovation process, as this is relevant in terms
158 of the information available on the NM and the adequacy of the risk assessment tools to be
159 used.

160 2) Preliminary risk assessment for those companies that already had a prototype NM / NEP or
161 set up a process and the type of risk was not clear.

162 3) Setting up SbD goals, this refers to the ambition of the company.

163 4) Identify SbD measures to achieve the desired explicitly stated goals.

164 5) Post SbD measure implementation risk evaluation and sustainability assessment to
165 demonstrate the safety of the NM / NEPs or process and evaluate the impact of the SbD
166 measures.

167 However, given the timescale of the project we did not follow the companies throughout the
168 entire innovation process. Some companies (Group Antolin, HIQ-nano, Nanomakers) had
169 already identified SbD measures and therefore not all the decisions made for each step is
170 described for every case study.

171 All the toxicity, exposure and risk assessments (RA), lifecycle assessments (LCA) as well as
172 socio-economic analysis (SEA) to facilitate the SbD process were undertaken by external
173 experts as most companies did not have the human resources to conduct such assessments.
174 The specific methods for these assessments have been reported separately in Jacobsen et al.
175 2020; Rodríguez-Llopis et al. 2020 and Salieri et al. 2020, but are briefly summarised as follows.

176 For the human RA, NanoSafer (Kristensen et al. 2010), the Swiss Precautionary Matrix (SPM,
177 Höck et al. 2008), Stoffenamanger-Nano (van Duuren-Stuurman et al. 2012), NanoRiskCat
178 (Hansen et al. 2011), the Weight of Evidence Approach (WoE, Hristozov et al. 2014) and the
179 Sustainable Nanotechnologies Project Decision Support System (SUNDS)¹ were considered.
180 Within each case study, we used the most relevant tool considering the domain of interest
181 (exposure, human hazard or overall risk), the SbD measures taken and the availability of
182 information.

183 The likelihood of occupational exposure was assessed following the exposure assessment
184 strategy and criteria for classification of exposure in EN17058:2018.

185 The criteria for the assessment of the human toxicity was done following the method
186 developed as part of the FP7 project "Nanosolutions" and adapted for NanoReg2 (Suarez-
187 Merino et al. 2018). Details of the toxicity assessments are reported in Jacobsen et al. 2020.

188 For the ecotoxicity assessment we followed the criteria in the European Regulation (EC) No.
189 1272/2008 on classification, labelling and packaging of substances and mixtures (CLP, 2008).
190 Details of the cytotoxicity in fish cell lines have been published in Kalman et al. 2019 and Barrick
191 et al. 2019.

192 The LCA was carried out to evaluate all the potential impact of the SbD measures, as before
193 embarking in any changes affecting the production, the company has to check their potential
194 influence not only in terms of hazard and exposure, but also in terms of energy efficiency,
195 resource depletion, emission of substances that contribute to different environmental impact
196 categories, like climate change (*i.e.* global warming potential, GWP), ozone depletion, etc. The
197 LCA was carried out using the software Simapro 8, the Ecoinvent v3.4 database as background
198 database, and the ReCiPe method (at Midpoint level) for the impact assessment (Pennington
199 et al 2004; Goedkoop et al. 2008).

200 For the Nanomakers case study we carried out a SEA where the base scenario was the use of
201 an electric vehicle battery without NMs.

¹ <https://sunds.gd/>

202 **3 Results**

203 Table 1 summarises the SbD pillar each company addressed, the situation before the SbD
204 implementation, the SbD measures adopted and the overall result.

205 **Table 1 shows a summary of the companies involved, NMs considered, their application, innovation stage and the SbD measures and results.**

NM/Company Country	Market Sector Stage Gate	SbD Pillar	Before SbD	SbD Measure	SbD Result	Conclusions/Benefits
Graphene AVANZARE (Spain)	Electric coatings & paints (Stage 2 Concept)	Safer process (minimal waste) (upscale production)	No previous prototype for comparison	SbD principles applied: - wet synthesis in water - recycle of waste into new batches Semi-automatic packing for dry product with LEV	Lower exposure as graphene is commercialized in wet form. Reduced handling of dry graphene No liquid waste & very low solid waste.	Significant improvement in product sustainability compared to other synthesis
CNF GRUPO ANTOLIN (Spain)	Automotive (Stage 5 Market entry)	Safer NM (lower toxicity) Safer process (upscale production)	Exposure risk in production & surface treatment stages High hazard potential due to HARN. Impact driven by high energy resources in production. Emission of greenhouse gases	Three candidate CNFs with different degree of impurities & crystallinity (GAtam, GANF, GANFg) Automated pneumatic transport Improve production process	Workers exposure reduced. Comparable for the 3 NMs ≠ CNT Environmental Impact reduced due to reduced emissions.	GATam toxicity comparable to GANF. GAtam production more efficient than GANF. Significant energy savings. Healthier working environment
Fluorescence NMs HIQ-NANO (Italy)	Biosensors (Stage 3 Prototype)	Safer NM (lower toxicity)	QD doped SiO ₂ High ecotoxicity due to the presence of Cd	Substitution of QD for a dye doped SiO ₂	Lower toxicity. Slightly higher exposure Similar process for both NMs. Changes driven by composition (elimination of Cd). Higher process efficiency: contribution to impact categories decrease up to 90%. Reduced exposure but high risk due to the HARN nature of the NM.	Similar risk. Reduction in all environmental impact categories: 5% (Ecotoxicity) to 75% (Ozone Depletion) lower impact per kg of material.
Ag nanowires NANOGAP (Spain)	Photovoltaic panels (Stage 5 Market entry)	Sustainable process	High Ag waste Impact driven by energy demand per Kg AgNF & generated waste Risk of exposure	Change synthesis parameters Automated filtration	Low release of Ag+ from trolley coating Low exposure: dip-coating method High energy consumption	Safer product as release of Ag+ during use is insignificant Sustainable product in terms of releases to the environment. Impact due to high electricity consumption & waste generation
Ag nanoparticles nanoComposix (Czech Republic)	Antibacterial coatings (Stage 3 Prototype)	Safer product (minimum release during use)	Potential consumer exposure to Ag ions	Design solution that limits release of Ag+ during use preserving functionality for longer. Selection of low exposure coating method Selection of purification method with low waste	Low release of Ag+ from trolley coating Low exposure: dip-coating method High energy consumption	Safer product as release of Ag+ during use is insignificant Sustainable product in terms of releases to the environment. Impact due to high electricity consumption & waste generation
Si based NMs NANOMAKERS (France)	Batteries for electric vehicles (Stage 3 Prototype)	Safer NM (lower flammability)	High dustiness High flammability Moderate toxicity	Carbon Coating Increase particle size Si@40nm, Si@C40nm & Si@C75nm	Reduced dustiness Reduced flammability Si@C40nm slightly more toxic Comparable environmental impact SEA: High uncertainty in these results due to lack of data	Considerable lower risk of ATEX for coated NMs. Comparable impact for the three NMs. Higher impact compared to using graphite (without NMs) but better performance A 10% increase in battery capacity generates more costs than benefits.

206 CNT: Carbon Nanotubes; CNFs: Carbon Nanofibers; GANF, GAtam, GANFg: Group Antolin CNFs with with graphitization degrees of 60, 70 and 90% respectively; HARN: High Aspect Ratio
207 Nanomaterials; NPs: nanoparticles; NMs: nanomaterials; ATEX: Explosive Atmosphere

208 3.1 Avanzare

209 The main goal of the Avanzare case study was the upscaling of graphene production using a new pilot
210 plant designed within the SbD concept (Table 1). The focus was on developing a safer process with
211 lower energy consumption and minimal workplace and wider environment emissions. This was
212 achieved by developing a wet synthesis method to minimise exposures in the workplace, using
213 graphite, a catalyser and water as main solvent for the exfoliation process. Water is used in a
214 continuous loop where at the end of the batch production process the remaining water is used in new
215 batches, thus eliminating liquid waste. Solid waste from cleaning & maintenance operations is
216 minimal. When the process is finished the graphene slurry is filtered by gravity. The filter retains the
217 solid material as a compact wet graphene dispersion which is immediately packed in plastic bags and
218 then aluminium bags. The graphene properties are shown in Table 2.

219

220 **Table 2 Graphene properties.**

Property	Value
Shape	Platelets
Size (bulk, nm)	Thickness: 1-10 Lateral size: 100-200
Surface area (m ² g ⁻¹)	>200 m ² g ⁻¹
Density (kg m ⁻³)	2-2.1

221

222 Graphene in a water medium is not compatible with all the intended applications and for some uses
223 the dry form is required. This dry graphene is dried in an oven after synthesis. Before the SbD
224 implementation graphene packing was done manually. An exposure assessment was carried out
225 where drying and packing were identified as having a high exposure. Two different SbD options were
226 considered: 1) packing within a fume-hood, 2) a semi-automatic system with local exhaust ventilation
227 (LEV). Option 2 was chosen as it reduced the manual handling and transport to the fume hood. .Task-
228 based personal exposures (of 90 min) of elemental carbon were reduced from 4.2 µg m⁻³ to 1.2 µg m⁻³
229 (average of the two operators involved in the task) thus demonstrating the efficacy of the SbD
230 measure.

231 The graphene in the dispersion and the dry graphene showed similar human toxicity except for the *in*
232 *vitro* inflammation where the graphene in dispersion showed a higher increase in cytokines (Table 3).
233 This might have been due to the presence of endotoxin in the samples, or because of a protective
234 effect of the BSA solution used with the dry graphene. A similar effect was observed with the CNF of
235 Grupo Antolin and this hypothesis is discussed in further detail in Jacobsen et al. 2020.

236

237 **Table 3 Human toxicity assessment of graphene (Avanzare).**

Assay	Graphene in liquid dispersion	Dry graphene	Conclusion
Cytotoxicity (24, 48, 72 hrs, 0.6,32,64 µg cm ⁻² A549, Impedance)	Non toxic	Slightly toxic (after 72 hours)	Dry seems to be slightly more toxic
ROS production (24 hrs, 25&50 µg cm ⁻² A549 & 3T3)	Low	Low	Comparable
In vitro Inflammation (24 hrs,32,64 µg cm ⁻² ,THP-1)	High (IL-8, TNF-α, & IL-1β)	High (IL-8)	Graphene in dispersion > dry graphene
In vivo instillation lung toxicity (rats, repeated exposure over 10 days, recovery up to 28 days)	NA	<ul style="list-style-type: none"> • Acute inflammation returning to basal level 28 days after exposure • No genotoxicity in lung & liver tissue (Comet assay). • No genetic mutation in blood (Pig-A gene mutation assay) • Alveolar & bronchi alterations. 	Comparable
Skin irritation (OECD 439)	Non-irritant	Non-irritant	Comparable
Ocular irritation (OECD 492)	Non-irritant	Non-irritant	Comparable

238 IC 50: half maximal Inhibitory concentration; ROS: Reactive Oxygen Species; NA: not available

239

240 *In vivo* data suggest that the dry form induces some acute inflammation response which returns to
 241 basal level 28 days after exposure. Nevertheless, lung histopathological analysis showed alveolar and
 242 bronchi alterations: hyperplasia associated with inflammation leading to bronchial obstruction
 243 (bronchiolitis obliterans).

244 To estimate the overall risk to workers we used NanoSafer, the SPM and the WoE. There were
 245 differences in the tools outputs. After the implementation of LEV, the WoE tool indicated, that the risk
 246 of exposure was low. In contrast, NanoSafer still showed that in the near field, exposure was still high
 247 which was not supported by the measurements. The SPM was not sensitive to the differences before
 248 and after the implementation of the exposure control measures but indicated a need for
 249 precautionary measures due to the intrinsic characteristics of the NM (reactivity and tendency to form
 250 aerosols < 10 µm).

251 Graphene was also tested for its aquatic ecotoxicity. Representative organisms from multiple trophic
 252 levels and ecosystems were selected in the present study to better establish a holistic environmental
 253 hazard assessment: *in vivo* on microalgae by studying the growth inhibition, on microinvertebrates by
 254 studying the acute toxicity on *Daphnia magna*, and *in vitro* on fish cell lines and mussel cells
 255 (cytotoxicity) (Table 4).

256

257 **Table 4 Environmental toxicity assessment (Avanzare).**

Ecotoxicity	Graphene in liquid dispersion	Dry graphene	Conclusion
Algal growth inhibition test (IC50) (OECD 201)	8.5 mg L ⁻¹ [8.0 - 9.2]	> 10 mg L ⁻¹	Dry form slightly less toxic
Daphnia magna acute immobilisation test (EC50) (OECD 202)	60 mg L ⁻¹ [37.9 – 89.7]	85 mg L ⁻¹ [54.8 – 136.2]	Dry form slightly less toxic
Cytotoxicity in fish cell lines (72 hrs, 128 µg ml ⁻¹) (IC50)			Liquid form non toxic
Lysosomal function (Neutral Red)	>256	>128	Test interferences in dry form didn't allow to test higher concentrations.
Mitochondrial activity (Alamar Blue)	> 128	> 16	
Membrane integrity (CFDA-AM)	>256	>31	
Cytotoxicity in hemocytes cells from mussels			
Mitochondrial activity (Alamar Blue)	>16	> 16	Non Toxic
Membrane integrity (CFDA-AM)	>256	58	Dry form more toxic

258 IC50: half maximal inhibitory concentration. ; CI95% are given in square brackets

259

260 The *in vivo* results showed the liquid dispersion form may be more toxic than the dry from. The *In vitro*
 261 test on fish cell lines and mussel cells showed no toxicity whatever the graphene form, dry or in liquid
 262 suspension. A slight effect was observed on membrane integrity after exposure to the dry form.
 263 However, some interferences with the test were identified.

264 The production of 50% graphene as a slurry (by eliminating the drying process) reduced the
 265 environmental impact by 18% mainly due to lower energy consumption.

266 3.2 Grupo Antolin

267 The company Grupo Antolin wanted to upscale production of CNFs focussing on safer and more
 268 sustainable CNFs as well as optimization of the production process to reduce emissions to the
 269 workplace and the environment.

270 The company uses two manufacturing processes, both based on CVD (Chemical Vapour Deposition)
 271 to make two types of CNFs (GANF and GATam). A third CNF (GANFg) was included in the study for
 272 comparison purposes. GANFg is synthesised as GANF but has a higher level of graphitization (Table 5).
 273 While the GANF and GATam materials are synthesised using different furnaces and operating times,
 274 they are oxidised (to clean the CNF surface) in the same way. The production process involves the
 275 following steps: synthesis in a furnace, collection and transport to the oxidation furnace, surface
 276 treatment through oxidation, collection, weighing, packing and preparing of dispersions.

277 The SbD measures included selection of the safer CNF (from three CNFs with different surface
 278 functionalization, degree of impurities and crystallinity (Table 5); automatization of the collection
 279 steps by pneumatic transport of the GATam, and an automated gravimetric dosing system for the
 280 dispersion and packaging stages of all the CNFs. A semi-automatic process with LEV as that applied in
 281 Avanzare to collect the dry graphene from the oven was not considered in this case since collection
 282 takes place from the furnace and a plume is generated when the furnace is opened. Therefore a fully
 283 automated system was considered safer.

284

285 **Table 5 Physical characteristics of the CNF (Grupo Antolin).**

Physical Characteristics	GANFg	GANF	GATam
Diameter (nm)	20-80	20-80	20-80
Length (nm)	200-10,000	200-20,000	100-10,000
Bulk density (g cm ⁻³)	0.08	0.06	0.08
Crystallinity (degree of graphitization, XRD)	≈ 99 %	≈ 70 %	≈ 60 %
Specific surface area (BET m ² g ⁻¹)	80-120	100-170	70-140
Carbon purity (TGA in N ₂)	>99%	>85%	>80%
Oxygen content (CHNS-O)		≈ 5 %	≈ 10 %
Electrical resistivity (Ohm m)	1*10 ⁻⁴	1*10 ⁻³	1*10 ⁻³

286

287 Adapted from the Grupo Antolin Carbon Nanofibres technical data sheet.

288

289 The results from the RA showed a risk reduction mostly driven by the reduction in the exposure due
 290 to the automatization of the GATAm collection (results shown in Rodríguez-Llopis et al. 2020), having
 291 the three fibre types comparable toxicities (Table 6).

292

293 The selected assays were based on the HARN nature of the NM, being inhalation the main
 294 occupational exposure route (Table 6).

295

296 **Table 6 Human toxicity assessment of CNFs (Grupo Antolin).**

Endpoint	GANFg	GANF	GATam	Conclusion
Cytotoxicity (IC50) (24, 48, 72 hrs, 0.6,32,64 µg cm ⁻² , A549, Impedance)	NA	No effect	No effect	Comparable
ROS generation (24hrs, 25&50 µg cm ⁻² A549)				
In BSA*	No evidence	Evidence	Evidence	GANF = GATam > GANFg
In Water#	Low	Moderate	Moderate	
<i>In vitro</i> Inflammation (24 hrs, 32, 64 µg cm ⁻² , THP-1)				
In BSA*	Low (IL-1β)	No evidence	No evidence	GANFg> GAtam=GANF
In water#	Low (IL-1β)	No evidence	No evidence	GANFg> GAtam=GANF
Genotoxicity (A549) Comet assay with & without Fpg Micronucleous (OECD 487)	Negative	Negative	Negative	
in BSA*	Equivocal	Positive	Positive	GANF=GAtam > GANFg
In water#	Negative	Equivocal	Equivocal	
In vivo instillation lung toxicity (mice) Genotoxicity (Comet assay)				
BAL cells	Positive	Positive	Positive	GANFg > GAtam=GANF
Lung	Positive	Negative	Negative	
Liver	Negative	Negative	Negative	
Inflammation	All materials were inflamogenic with a response similar to to Carbon Black Printex 90 (14 nm)			Comparable (GANFg show a faster return to baseline)
In vivo instillation lung toxicity (rats) Genotoxicity (Comet assay)				
BAL cells	Negative	NA	Negative	Comparable
Lung	Negative		Negative	
Liver	Negative		Negative	
Pig-A gene mutation	Negative	NA	Negative	Comparable
Inflammation	Temporary	NA	Lasted over 3 days but return to baseline level after 28 days except for TNF-α	Higher for GATam
Hystopathology	Bronchiolitis obliterans that tend to decrease over time		Bronchiolitis obliterans that tend to decrease over time	More frequent for GATam
Skin irritation (OECD 439)	Non-irritant	Non-irritant	Non-irritant	Comparable
Ocular irritation (OECD 492)	Non-irritant	Non-irritant		Comparable

297 IC50: half maximal inhibitory concentration; ROS: reactive oxygen species; NA: not available. BSA: bovine serum albumin. Fpg;
 298 formamidopyrimidin glycosylase *High energy sonication process (Nanogenotox dispersion protocol), which led to significant
 299 fibre shortening. #Dispersion in water with very mild or no sonication. Rats and mice were exposed to equivalent doses. Analysis
 300 were performed 1, 3, and 28 days after exposure. Full details are reported in Rodríguez-Llopis et al. 2020.
 301

302 Overall GANF and GATam showed a similar toxicological profile and the slight differences in
 303 crystallinity and impurity content (Table 4) did not affect their hazard response. The comparison with
 304 the GANFg fibres (with a higher crystallinity but without impurities) yield different results in the *in*
 305 *vitro* and *in vivo* tests. The results from the *in vitro* inflammation showed a higher response for GANFg,
 306 but in the *in vivo* study in mice the response was similar for the three materials whilst for the *in vivo*
 307 study in rats GATam showed a higher inflammation response than the GANFg.

308
 309 The lower effect on ROS production with the use of BSA was attributed to the formation of a BSA
 310 protein corona around the fibres which affects their interaction with the cells decreasing their
 311 biological response. Previous studies have reported this effect with carbon materials (Sengupta et al.
 312 20015; Bai et al. 2016). Further details on the toxicity assessment are reported in Rodríguez-Llopis et
 313 al. 2020.

314 The CNFs were also tested for their environmental toxicity in algae, daphia magna, fish cells and
 315 mussels (Table 7).

316

317 **Table 7 Environmental toxicity assessment of CNF (Grupo Antolin).**

Endpoint	GANFg	GANF	GATam	Conclusion	
Algal growth inhibition test (IC50) (OECD 201)	8.5 mg L ⁻¹ [7.4 – 12.1]	3.1 mg L ⁻¹ [2.4 - 3.3]	2.1 mg L ⁻¹ [1.9 - 2.3]	GATam ≈ GANF > GANFg	
Daphnia magna acute immobilisation test (EC50) (OECD 202)	5.8 mg L ⁻¹ [4.8 - 7.8]	9.9 mg L ⁻¹ [8.1 – 12.0]	8.9 mg L ⁻¹ [7.2 - 10.6]	Comparable	
Daphnia magna chronic toxicity test (EC50) (OECD 211)	6.2 mg L ⁻¹ [4.7 - 8.2]	1.6 mg L ⁻¹ [1.4 - 1,8]	0.32 mg L ⁻¹ [0.1 - 0.4]	GATam > GANF > GANFg	
Cytotoxicity in fish cell lines (72 hrs) (IC50)	Neutral Red	> 256 mg L ⁻¹	256 mg L ⁻¹	165 mg L ⁻¹	GATam > GANF > GANFg
	Alamar Blue	32.0 mg L ⁻¹	18.9 mg L ⁻¹	46.7 mg L ⁻¹	GANFg > GANF > GATam
	CFDA-AM	252 mg L ⁻¹	37.6 mg L ⁻¹	89.9 mg L ⁻¹	Non Toxic
In vivo test on mussels	No mortality after 1 day of exposure Mussels extremely efficiency filtering CNF			Non Toxic	

318 IC50: half maximal inhibitory concentration; EC50: half maximal effect concentration. CI95% are given in square brackets.
 319 Further details on the ecotoxicity are reported in Barrick et al. 2019.

320

321 The data obtained *in vivo* show that the CNFs are ecotoxic toward the freshwater organisms. GANF
 322 and GATam have a comparable ecotoxicity as observed in the human toxicity assessment while GANFg
 323 appears to be less toxic.. Further details on the ecotoxicity have been published in Barrick et al. 2019
 324 and Kalma et al. 2019.

325

326 Regarding the exposure the WoE model indicates, in accordance with the experimental results, that
 327 the potential exposure after the SbD implementation, is low, NanoSafer indicated that for some
 328 stages, storage and dispersion in water of GATam, exposure is still high. The SPM was not sensitive to
 329 the differences before and after the SbD indicating a need for precautionary measures due to intrinsic
 330 characteristics of the NM (reactivity and stability).

331

332 The LCA showed that the impact of the emission during production has limited impact on the global
 333 environmental impact. Nevertheless, the reduction of the emissions due to the SbD implementation
 334 was noticeable. The method for producing GATam CNF was more energy efficient, due to a higher
 335 yield of the CVD reaction, and presented a lower environmental impact than the GANF method. A full
 336 description of the case study is reported in Barruetabeña et al. 2020.

337

338 **3.3 HIQ-nano**

339 HIQ-nano manufactured Quantum Dots (CdSe) doped silica nanoparticles used as tracers in vitro
 340 biological testing. The SbD goal was to develop a new particle with a lower toxicity to reduce the risk
 341 to humans and the environment but maintaining the fluorescence properties. The SbD measure was the
 342 substitution of CdSe for an organic pigment. HIQ-Nano came up to the decision for this specific SbD
 343 option based on safety considerations of the pigment that appeared better than the known toxicity of
 344 Cadmium and their good performance as cellular marker in vitro .

345 Therefore, the case study focused on the comparative functionality and risk assessment of both
 346 particles. The dye doped SiO₂ showed higher fluorescence properties compared to the QDs. QDs-
 347 doped particles exhibited a much more varied appearance, as well as an increased background
 348 compared to the dye doped SiO₂. Both particles were synthesised in an enclosed system with a larger
 349 duration for the dye doped SiO₂ NPs. The production process in terms of likelihood of exposure was
 350 low for both NPs. The overall risk was estimated using the CB Nanotool, the Swiss SPM and WoE. The
 351 LCA was only applied to the production stage as the particles are used in the human body and
 352 therefore a full LCA is not appropriate. The toxicity characterization is shown in Tables 8 (human
 353 toxicity) and Table 9 (environmental toxicity).

354 **Table 8 Human toxicity assessment of fluorescence NPs (HIQ-nano).**

Endpoint	QDs doped SiO ₂ NP	Dye doped SiO ₂ NP	Conclusion
Cytotoxicity (24, 48, 72 hrs, 0.3, 3, 16, 33 µg cm ⁻² , A549, Caco-2, HFF-1)	No effect	No effect	Comparable
ROS (5 min, 30min, 1h, 3h, 8h 24h, 3, 33, µg cm ⁻² Caco- 2,)	Evidence; 30 min to 3h	Evidence; 30 min to 8h	Comparable
ROS (96 hrs, 0.3, 3, 16, 33, µg cm ⁻² Caco-2)	No evidence	No evidence	Comparable
In vitro inflammation (24 hrs, 10, 104 µg ml ⁻¹ , RT-PCR in HFF-1 cells)	Slight upregulation of gene expression at 8-30h exposures. Strongest effect to induce IL6 and IL8 at 24-30 h	A significant upregulation of gene expression at 8-30h exposures. Strongest effect to induce IL6 and IL8 at 24-30 h	Dye > QD SiO ₂ NPs.
Genotoxicity (A549) Micronucleus assay (OECD 487)	Equivocal although a statistically significant increase with conc 1 & 5 nM	Equivocal although statistically significant increase with conc of 5 nM	QDs doped SiO ₂ slightly > dye doped SiO ₂

355 **Table 9 Environmental toxicity assessment of fluorescence NPs (HIQ-nano).**

Endpoint	QDs doped SiO ₂ NP	Dye doped SiO ₂ NP	Conclusion
Cytotoxicity in fish cell lines (IC50) 0.2-256 µg/mL ⁻¹			
Neutral Red	> 256 mgL ⁻¹	119 mgL ⁻¹	Dye doped SiO ₂ > QDs doped SiO ₂
Alamar Blue	> 256 mgL ⁻¹	88.8 mgL ⁻¹	
CFDA-AM	> 256 mgL ⁻¹	156 mgL ⁻¹	

356

357 The results from NanoSafer and the SPM showed an increased risk after the SbD implementation
358 (substitution of QDs by a dye) driven by the longer exposure periods and frequency of the production
359 process. However, this potential risk was not confirmed in the exposure measurement campaign
360 (results not shown).

361 The WoE was sensitive to the reduction in the hazard and as the hazard score due to the presence of
362 toxic substances for the dye doped SiO₂ NP was lower (medium, compared to high for QDs due to the
363 higher toxicity of the Cadmium present in the latter) the overall risk was reduced.

364 The LCA showed the major impact was due to the waste reduction during the production of the dye
365 doped SiO₂ NPs due to the smaller amount of water required. Ozone depletion and fresh water
366 ecotoxicity was also reduced with the introduction of the dye doped SiO₂ NPs.

367 3.4 NanoGap

368 NanoGap produced silver nanofibers for electrical applications. This case study was focused on the
369 safer production pillar. The goal was to investigate potential exposure scenarios and introduced SbD
370 measures to optimize the production process so as to reduce the amount of waste (silver nanofibers,
371 unreacted silver and solvent) and the environmental impact.

372 To optimize the production process the different forms of silver during the purification process and in
373 the final waste were characterized. Eighty percent of the silver mass in the waste was in the shaped
374 of pseudo-spherical silver particles and the rest as nanowires. A first approach was to design a
375 recycling process for the silver in the waste. However, the LCA results for the production process
376 showed this had a high impact in terms of the energy and resources needed. Instead the production
377 process (duration, temperature and pressure) was modified to reduce the amount of waste
378 generated.

379 The process characteristics before and after the SbD implementation are shown in Table 10.

380 **Table 10 Waste generation before and after the SbD implementation (NanoGap).**


Parameter	Before SbD	After SbD
Ag nanowires dimensions	120 nm & > 20000 nm long	70 nm & >25000
Reaction rate (%)	41	90
Handling time (hrs)	28	1.7
Volume of solvent waste (L)	256	22
Ag waste (gL ⁻¹)	1.40	0.2

381

382 The new process resulted in a 50% reduction of the silver waste. The nanofibers were however slightly
383 shorter (70 nm smallest dimension compared to 120 nm). The conductivity was within the desired
384 range.

385 The exposure assessment revealed the presence of airborne nanofibers. Despite the entire process
386 was wet, any splashes during product collection or items contaminated with the solution can give raise
387 to suspended nanofibers once the solvent evaporates (Figure 1).

388



389 **Figure 1 SEM (left) and EDX (right) of silver nanofibers collected during the production process.**

390 A protocol for collection and cleaning was established to minimize the splashes and to clean any
 391 devices and surfaces in contact with the solution.

392 The exposure to workers before and after the SbD measures was also evaluated using several control
 393 banding tools. The SPM indicated the need of a precautionary need mostly driven by the hazard
 394 properties of the rigid Ag nanofibers. No differences were found before and after the implementation
 395 since good hygiene practices is not a parameter considered in the tool. The NanoSafer classified the
 396 risk after the SbD implementation as higher due to the smaller diameter of the nanofibers that results
 397 in a higher aspect ratio of the NM.

398 3.5 nanoComposix

399 The nanoComposix case study dealt with the development of antibacterial coatings for trolleys using
 400 silver nanoparticles (AgNPs). The overall goal of the case study was to determine if AgNPs used in a
 401 solution to coat trolleys were safe for workers and consumers and suitable for market application
 402 before moving on to pilot production. The trolleys were made of zinc-coated unvarnished material,
 403 and the AgNP were added to the coating solutions. Two different methods for applications of AgNPs
 404 were taken into consideration: a) dip coating (30 nm AgNPs); b) spraying (75 nm AgNPs). Table 11
 405 shows the particle characteristics.

406
 407 **Table 11 Physico-chemical characteristics of AgNPs (nanoComposix).**

Parameters	Ag NP-1	Ag NP-2
Matrix	NPs in lacquer	NPs is spray
Primary particle size (nm) (TEM, crystallite size)	30	75
Shape	Spherical	Spherical
Surface area (TEM)	19.4 m ² g ⁻¹	7.4 m ² g ⁻¹
Silver concentration	30 mg L ⁻¹	30 mg L ⁻¹

408
 409 AgNPs are well established to be an antibacterial effective method for the treatment of skin bacterial
 410 infections. The Ag ions are released from the particle surface, with higher releases for larger surface
 411 area and smaller AgNP. Therefore the 30 nm Ag NPs might lead to a worst exposure scenario
 412 compared with larger particles. Also, edges and damaged particle surfaces may release more ions than
 413 necessary leading to a reduction in product life time and an increase in potential hazard as an excess
 414 of AgNP on the skin can cause irritation or argyria (grey-black staining of the skin and mucous
 415 membranes) in damaged skin (Hadrup et al. 2018). The released of silver from the trolley following
 416 incubation with artificial human sweat (Midlander et al. 2016), was determined by ICP-OES following
 417 ISO 11885:2009 (Table 12).

418 The antibacterial properties of the trolley's handle samples were tested by Agar diffusion test using
 419 *Escherichia coli* (K-12) and *Bacillus subtilis* (NCIB 3610) as reference strains for Gram-negative and
 420 Gram-positive bacteria, respectively.

421 The release of Ag NPs due to abrasion of the trolley parts was studied using the TABER[®] abrasion test
422 (ASTM, 1996). The stress applied with the abrader simulates the typical applied in a domestic
423 solicitation and addresses the question of possible long-term exposure (Vorbau et al., 2009; Hassan et
424 al 2010). Ag NPs were not identified in the filter samples of the aerosols analysed by Transmission
425 Electron Microscopy-Energy Dispersive X-ray Spectroscopy (TEM/EDS) for either the coated or the
426 sprayed trolley parts.

427 Cytotoxicity, genotoxicity and ROS experiments were carried in human epidermal cells (HaCat) as the
428 main exposure path was dermal (Table 12). Cells were incubated in the artificial sweat samples in
429 contact with the coated parts of the trolley.

430

431 **Table 12 Human toxicity assessment for Ag NPs (nanoComposix).**

Endpoint	30 nm AgNP Coated technology	75 nm AgNP "Sprayed " technology	Conclusion
Release of Ag+ (ISO 11885:2009)	11 ± 3 ppm	10 ± 2 ppm	Comparable
Antibacterial activity against E.coli*, 1 year after production (diffusion test: 2, 4, and 24 h)	13, 17, and 51 %	24, 37, and 45%	Comparable Higher bactericidal effect at prolonged contact
Cytotoxicity (15 and 30 min, 1h , HaCat cells,)	No significant difference in viability compared to the uncoated control trolley.	No significant difference in viability compared to the uncoated control trolley.	Comparable
Cytotoxicity (15, 30 mins, 1h 3D cell model (NHEK))	Moderate to Low	Low	Comparable
ROS generation 15, 30 mins, 1h, HaCat cells)	No significant difference from control	No significant difference from control	Comparable
Genotoxicity (HaCat cells) Micronucleus assay (OECD 487)	Equivocal	Equivocal	Comparable
Skin irritation, at 15 min, 30 min, 1h (OECD 439)	Non-irritant	Non-irritant	Comparable

432 NHEK: normal, human-derived epidermal keratinocytes

433

434 For the RA screening, NanoRiskCat and Swiss Precautionary Matrix were selected as control banding
435 tools to assess the risk of consumers for both applications a) dip coating (30 nm AgNPs); b) spraying
436 (75 nm AgNPs). This was accompanied by a complete RA based on scientific literature.

437 The control banding tools suggests possible exposure to workers and possible hazard, for both
438 materials and processes (coating and spraying).

439 The LCA included the production of the 30 nm AgNPs, production of the lacquer containing the AgNPs
440 and the actual dip coating process. At the level of production of AgNPs the functional unit of 1 kg of
441 nanoparticle was applied. The LCA results revealed that the electricity consumption -used during the
442 actual NP manufacturing process was the main contributor (with 75-92%) to all the impact categories
443 investigated, followed by the consumption of chemicals (5-45%). The production of the Ag containing
444 solution is a simple process in which a liquid solution is produced by mixing AgNPs and water. In this
445 process no energy is consumed and no emissions are released. Therefore, the potential impacts are
446 attributed to the liquid solution in which AgNPs are dispersed. To account the potential impact of the
447 "dip coating process" 1 m² of treated (trolley) surface was chosen as functional unit. The treatment of
448 the waste water is the main contributor to the overall impacts, followed by the used nano-Ag solution
449 (10-35%).

450 3.6 Nanomakers

451 The company Nanomakers wanted to modify anode nanoparticles to increase the performance of
452 Lithium-ion batteries. The company used pure silicon NPs due to their higher electrochemical
453 performance compared to graphite. The SbD goal was to achieve a NP with a higher stability and
454 performance, lower risk of explosion and low human and ecotoxicity.

455 In order to achieve that goal the company increased the NP size from 40 to 75 nm (reducing the
456 alveolar deposition of inhaled aerosols) and coated the NP with amorphous carbon which increased
457 the conductivity, increased stability and reduced the dustiness (and the explosivity as a consequence).

458 Tables 13 and 14 show the results from the human and environmental hazard assessment
 459 respectively. For the RA we used control banding tools (i.e. NanoRiskCat and Precautionary Matrix),
 460 the SUNDS decision system tool and WoE. LCA and SEA were also carried out.

461 The carbon coating resulted in a reduction of the dustiness from 1,163 (Si, 40 nm) to 150 (Si, 40 nm
 462 carbon coated) and to 21 mg kg⁻¹ (Si, 75 nm carbon coated) resulting in a reduction of the explosion
 463 severity to class 1 for Si 75 nm carbon coated (comparable to some bulk silicon powders and sugar).

464 **Table 13 Human and environmental toxicity assessment for pure Si 40nm, Si 40 nm and Si 75nm**
 465 **coated with carbon referred to as Si@C40 nm and Si@ 75 nm respectively (Nanomakers).**

Endpoint	Si 40 nm	Si@C40 nm	Si@C75 nm	Conclusion
Cytotoxicity (24 hrs, 1, 3, 10, 20 µg cm ⁻² A459/THP-1)	Slightly toxic	No effect	No effect	Si > Si@C40 = Si@C75
ROS generation (24 hrs, 1, 3, 10, 20 µg cm ⁻² A459/THP-1)	No effect	No effect	No effect	Comparable
<i>In vitro</i> Inflammation (24 hrs, 1, 3, 10 µg cm ⁻² A459/THP-1)	High (IL-1β, IL-6) Negative (IL-8 & TNF-α)	High (IL-1β ,IL-6) Low (TNF-α) Negative (IL-8)	High (IL-1β , IL-6) Negative (IL-8 & TNF-α)	Si = Si@C75 > Si@C40 Si@C40 > Si = Si@C75
Genotoxicity (A549) Comet assay with & without Fpg	Negative	Negative	Negative	Comparable
Micronucleous (OECD 487)	Equivocal	Equivocal	Equivocal	Comparable
<i>In vivo</i> instillation lung toxicity (rats)* Genotoxicity (Comet assay)	BAL cells Negative Lung Negative Liver Negative	Negative Negative Negative	NA	Comparable
Pig-A gene mutation	Negative	Negative	NA	Comparable
Inflammation	Temporary	Persistent after 28 days exposure	NA	Si@C40nm > Si
Histopathology	Bronchiolitis obliterans but tend to decrease in time	Bronchiolitis obliterans but tend to decrease in time	NA	More intense lesions for Si@C40
Skin irritation (OECD 439)	Non irritant	Non irritant	Non irritant	Comparable
Ocular irritation (OECD 492)	Non irritant	Non irritant	Non irritant	Comparable

466 ROS: reactive oxygen species; Fpg; formamidopyrimidin glycosylase; * single exposure, recovery up to 28 days.

467 The *in vitro* data indicates Si has a higher toxicity than the coated NPs. However the *in vivo* data, which
 468 represents the toxicity in the long term (lungs were examined after 28 days of exposure), showed that
 469 the Si@C40 NPs were slightly more toxic than Si because of their persistent inflammation parameters
 470 (cytokine secretion and BAL cells influx).

471

472 **Table 14 Environmental toxicity assessment of pure Si 40nm, Si 40 nm coated with carbon (Si@C40**
 473 **nm), and Si 75 nm coated with carbon Si@C75 nm.**

Endpoint	Si 40 nm	Si@C40 nm	Si@C75 nm	Conclusion
Algal growth inhibition test (IC50) (OECD 201)	No effect (max con. 5 mgL ⁻¹)	No effect (max con. 5 mgL ⁻¹)	No effect (max con. 5 mgL ⁻¹)	Comparable (no effect)
Daphnia magna acute immobilisation test (EC50) (OECD 202)	>100 mgL ⁻¹	>100 mgL ⁻¹	>100 mgL ⁻¹	Comparable (no effect)
Daphnia magna chronic toxicity test (OECD 211)	No effect (max con. 25 mgL ⁻¹)	No effect (max con. 25 mgL ⁻¹)	No effect (max con. 25 mgL ⁻¹)	Comparable (no effect)
Cytotoxicity in fish cell lines (EC50) CFDA-AM	129 mgL ⁻¹	123 mgL ⁻¹	>256 mgL ⁻¹	Comparable for Si@40nm & Si@C40nm. No effect for Si@C75nm

474 IC50: half maximal inhibitory concentration; EC50: half maximal effect concentration. CI95% are given in square brackets.

475

476 The three NMs had comparable ecotoxicities except for the cytotoxicity in fish cell lines where the 40
 477 nm NMs (coated and uncoated) showed a higher toxicity than Si@C75nm.

478

479 The control banding tools NanoRiskCat and the Swiss Precautionary Matrix were not sensitive to the
 480 small differences between the materials and processes and provided the same risk band: medium
 481 exposure risk for consumers, workers and the environment and insufficient data to assess the hazard
 482 effects. The results of the Swiss Precautionary Matrix indicate the need of precautions for workers
 483 and the environment.

484 NanoSafer was thought to be the most appropriate tool in this case since the material was a powder
 485 and there was available data on the dustiness. However, the coated materials, which have medium
 486 (SiC@40nm) and low dustiness (Si@C75nm) compared to the high dustiness of the uncoated
 487 materials, resulted in a higher risk since coatings are a cause of concern in NanoSafer (by principle).

488 The characterization factors (fate factor, effect factor and an exposure factor) estimated as part of the
 489 LCA analysis for the three NPs were comparable, despite the Si carbon coated NPs required an extra
 490 production step and an additional raw material.

491 For the SEA analysis the base scenario for comparison was the use of graphite (without NMs). The SEA
 492 results showed that the increase in performance did not overcome the higher production costs.
 493 However, due to the lack of data several assumptions were made and the data uncertainty was high.

494 4 Discussion

495 This study demonstrated the implementation of the Nanoreg2 SbD concept which aims to identify,
 496 estimate and reduce uncertainties and risks for humans and the environment along the entire value
 497 chain, ideally starting at the earliest stage of the innovation process.

498 Although most companies carried out an assessment to comply with the CLP Regulation, a full and
 499 integrated process where functionality, human and environmental aspects are considered together
 500 was not followed in any of the companies. During the discussions with the task force to approve the
 501 SbD proposal it was evident that the approach required the involvement from different departments
 502 (R&I, production, finance) and expertise that in some cases was not available at the company
 503 especially in regard to the toxicity and risk assessment. The issue of how safe a NM/NEP and process
 504 had to be so as to be labelled SbD was also extensively discussed and the creation of a SbD label was
 505 suggested to incentive other companies. The main view was in line with Hjorth et al. 2017: SbD is a
 506 process rather than a "property". SbD can be used to address concerns at an early stage and show

507 that a clear and defined process is used to address potential and actual hazards associated with NMs.
508 Also, the process is not linear but iterative, if a reduction in risk is not achieved the cycle starts again
509 until a compromise between risk, functionality and cost is reached.

510 Overall the companies were satisfied with the process and the results although the overall output
511 diverged from the stated goal, as for example in HIQ-nano where the substitution of the QD for the
512 dye did not result in a significant reduction of toxicity. Others where the SbD was based at the start
513 like Avanzare and nanoComposix acknowledged the advantages of assessing the risk along the
514 functionality as the innovation progresses.

515 The results from the case studies highlighted the need to better understand the extent of changes
516 required in the NMs / NEPs properties to produce a significant change in the hazard and exposure. It
517 is important to also understand the impact of such change on other properties during large scale
518 production, since in some instances some safety aspects are improved at the cost of others. For
519 example, in the Group Antolin case study the higher crystallinity was achieved by a higher temperature
520 process, and the resulting CNFs had lower impurities. The differences in crystallinity did not result in
521 significant differences in the inflammation response, possibly because of the higher content in
522 impurities of the CNF with lower crystallinity. Also, further work is required on the relationships
523 between physico-chemical properties, hazard and functionality.

524 In the case of Nanomakers, the results from the in vitro and in vivo assays did not agree, so it was
525 difficult to conclude the amorphous carbon coating reduced the toxicity. The coating did reduce the
526 dustiness of the particles and therefore the risk of explosion and the worker's exposure. The coating
527 also increased the conductivity and stability of the particles. However, the socioeconomic assessment
528 for their use in lithium-ion batteries for cars, when compared to the used of graphite, showed that the
529 increase in performance did not overcome the higher production costs.

530 For the toxicity assessment, OECD guidelines were used when available or Standard operating
531 procedures (SOP) developed in other projects (eg. NanoTEST, NANoREG, Nanosolutions). However,
532 not all the assays have an SOP or guideline. Moreover, in some cases there is more than one assay
533 suitable to reach the same endpoint. Different assays with one endpoint could also give different
534 results, therefore several assays have been used in each case study for the same endpoint. The same
535 could be said about the experimental systems, for the same assay different cell lines or primary
536 cultures could be used and each one could respond in a different way to the exposure of NMs. In the
537 case studies, cell lines that were closer to the exposure routes of the NMs were used. A
538 standardisation of assays will facilitate the testing and the compliance with regulation. This
539 standardisation is now being performed in some ongoing H2020 EU projects, such as PATROLS
540 (<https://www.patrols-h2020.eu/>) or RiskGONE (<https://riskgone.wp.nilu.no/>) and this will overcome
541 some of the limitations of the assays performed.

542 There is no single tool available that can estimate the overall risks, offer SbD solutions based on the
543 risks and estimate the impacts of such solutions. The selection of the risk assessment tools will depend
544 on the safety aspect being addressed (human hazard, environmental fate, human exposure) and the
545 availability of the information needed. A preliminary risk assessment was performed for all the case
546 studies using at least two different control banding tools. This exercise allowed to identify point of
547 concern where SbD measures could be needed and also gaps in information that should be filled. For
548 comparative purposes The Swiss Precautionary Matrix that covered different safety aspects (workers,
549 environment, consumers) was used in all case studies It is also a simple tool that uses default values
550 for unknown information. The other tool varied according to the case study. Nanosafer, Control
551 Banding Nanotool or Nanoriskcat were used. Control banding tools are less data demanding but they
552 give a qualitative result so they are more appropriate for risk screening for the early stages of the
553 innovation process identifying points of concern. For the purposes of SbD, where small differences in
554 the properties of NMs and production processes are compared, control banding tools are, in general,
555 not sensitive enough. These tools were designed under the precautionary principle and, in general,

556 are too conservative. However, they are still useful for the purposes they were created as a screening
557 tool to prioritize areas or NM of concern before implementing SbD.

558 To determine the effectiveness of the SbD measures semi-quantitative or quantitative although more
559 data demanding tools such as SUNDS, GUIDEnano or WoE may be required for a comparative risk
560 assessment. The disadvantage is that the required data is sometimes not available in the first stages
561 of the innovation.

562 The use of grouping approaches (e.g. Giusti et al. 2019) to read-across hazard endpoints of unknown
563 NMs, based on a source material would have helped to reduce the number of tests carried out and
564 speed up the hazard assessment. However, this approach was not used due to the lack of sufficient
565 data available on the studied NMs at the time of the implementation.

566 In general, smaller companies reckoned it would have been difficult to implement SbD without the
567 assistance of the technical experts. The main barriers identified were the terminology around SbD at
568 the start of the project, the lack of data available, the cost of the testing required to produce data, the
569 time invested in the planning, data gathering and interpretation, a clear path to demonstrate the SbD
570 result, and the lack of regulation. Despite these challenges most companies showed an interest to
571 apply SbD in future innovations.

572 Based on the experience and knowledge gained through this study a guidance for the nanotechnology
573 industry was developed and it is provided in Sánchez Jiménez et al. 2020. However to overcome the
574 barriers identified during the implementation of a trusting environment as that described in
575 Soeteman-Hernandez et al. 2018 is essential to share data, experiences and expertise. The risk
576 assessment tools have to be more sensitive to changes in hazard and exposure, and toxicity assays
577 have to be standardized so data is comparable.

578 5 Conclusion

579 This study has showed the complexities and barriers of the practical implementation of the NanoReg2
580 SbD concept as well as the benefits of reducing risk uncertainties along the innovation process instead
581 of doing it at the end.

582 SbD, or similar concepts are implemented in other sectors. Whilst different contexts bring different
583 challenges it is important to collate the shared experiences and knowledge to encourage and facilitate
584 the application of the concept to all industrial sectors. Overall the nanotechnology companies that
585 participated in this study found value on the application of SbD. Avanzare shifted to zero liquid waste
586 and almost eliminated employee handling of graphene in powder form. Group Antolin reduced
587 workers exposure and was able to select the most efficient method for the production of CNFs (the
588 method used for GATam CNFs). HIQ-nano was able to compare the toxicity of the both materials and
589 think of new solutions. NanoGap reduced in 50% the silver waste. Nanomakers reduced the risk of
590 explosion, workers exposure and was able to assess the financial viability of the SbD measures.

591 The implementation of SbD in the nanotechnology sector requires expertise in material science,
592 chemical engineering, toxicity, exposure and risk and considerable amounts of data. To streamline the
593 implementation and make it affordable for companies data on physico-chemical properties, hazard
594 and exposure should be shared through robust and reliable databases. Training on how to use the
595 databases and risk assessment tools should be provided. This would facilitate the SbD implementation
596 and will further progress the development of sustainable NEPs.

597 6 Acknowledgements

598 This work was performed within the EU project NanoReg2, funded by the Horizon 2020 Framework
599 Programme of the European Union under Grant Agreement Number 646221. We gratefully
600 acknowledge the contributions of all the industrial partners and the entire NanoReg2 consortium for
601 their continuous support and advice on the case studies.

602 All the *in vivo* experiments were performed in compliance with EU Directive 2010/63/EU for animal
603 experiments and institutional guidelines.

604 7 Competing interests

605 All companies that participated in the study commercialised NMs. GAIKER and INERIS have worked as
606 consultants for Grupo Antolin and Nanomakers respectively. GAIKER and Safenano (IOM) have worked
607 as consultants for Avanzare.

608

609

610 REFERENCES

- 611 Afantitis, A., Melagraki, G., Tsoumanis, A., Valsami-Jones, E., Lync, I. 2018. A nanoinformatics decision
612 support tool for the virtual screening of gold nanoparticle cellular association using protein
613 corona fingerprints. *Nanotoxicology*. 12, 1148-1165
- 614 Afantitis, A., Melagraki, G., Isigonis, P., Tsoumanis, A., Varsou, DD., Valsami-Jones, E., Papadiamantis,
615 A., Ellis, LA., Sarimveis, H., Doganis, P., Karatzas, P., Tsiros, P., Liampa, I., Lobaskin, V., Greco,
616 D., Serra, A., Kinaret, PAS., Saarimäki, LA., Grafström, R., Kohonen, P., Nymark, P.,
617 Willighagen, E., Puzyn, T., Rybinska-Fryca, A., Lyubartsev, A., Alstrup Jensen, K.,
618 Brandenburg, JG., Lofts, S., Svendsen, C., Harrison, S., Maier, D., Tamm, K., Jänes J., Sikk, L.,
619 Dusinska, M., Longhin, E., Rundén-Pran, E., Mariussen, E., El Yamani, N., Unger, W., Radnik,
620 J., Tropsha, A., Cohen, Y., Leszczynski, J., Ogilvie, Hendren, C., Wiesner, M., Winkler, D.,
621 Suzuki, N., Yoon, TH., Choi, JS., Sanabria, N., Gulumian, M., Lynch, I. 2020. NanoSolveIT
622 Project: Driving nanoinformatics research to develop innovative and integrated tools for in
623 silico nanosafety assessment. *Computational and structure Biotechnology*. 18, 583-602
- 624 Anastas, P. and Warner, J. 2000. *Green Chemistry: Theory and Practice*. Oxford University Press.
625 Oxford, UK. ISBN: 9780198506980
- 626 ASTM International, 1996. Standard test methods for dry abrasion mar resistance of high gloss
627 coatings ASTM D6037.
- 628 Bai, W., Wu, Z., Mitra, S., Brown, J.M. 2016. Effects of multiwalled carbon nanotube surface
629 modification and purification on bovine serum albumin binding and biological responses. *J*
630 *Nanomater*. 2016,2159537.
- 631 Barrick, A., Châtel, A., Manier, N., Kalman, J, Navas, J.M., Mouneyra, C. 2019. Investigating the Impact
632 of Manufacturing Processes on the Ecotoxicity of Carbon Nanofibers: A Multi-Aquatic
633 Species Comparison. *Environmental Toxicology and Chemistry*. 38, 2314-2325
- 634 Barruetabeña, L., Gómez, P., Merino, C., García Heras, E., Salieri, B., Hischier, R., Suarez-Merino, B.,
635 Micheletti, C., Sánchez Jiménez, A., Jacobsen, N.R., Hadrup, N., Trouiller, B., Navas, J.M.
636 Kalman, J., Apostolova, M.D., Mouneyrac, C., Barrick, A., Chatel, A., Dusinska, M., Runden
637 Pla, E., Jensen KA, Rodríguez Llopis, I. 2020. Industrial Implementation of a Safe by design
638 approach for the production of carbon nanofiber. (In preparation for submission to
639 NanoImpact)
- 640 Bello, D., Wardle, B.L., Yamamoto, M., Guzman de Villoria, R., Garcia, E.J., Hart, A.J., Ahn, K.,
641 Ellenbecker, M.J., Hallock, M. 2009. Exposure to nanoscale particles and fibers during
642 machining of hybrid advanced composites containing carbon nanotubes. *J Nanopart Res*. 11,
643 231–249.
- 644 Bouillard, J., Vignes, A., Dufaud, O., Perrin, L., Thomas, D. 2010. Ignition and explosion risks of
645 nanopowders, *Journal of Hazardous Materials*. 181, 873–880.
- 646 Casals, E., Gonzalez, E, and Puentes, V.F. 2012 Reactivity of inorganic nanoparticles in biological
647 environments: insights into nanotoxicity mechanisms. *J. Phys. D. Appl. Phys.* 45, 443001
- 648 Cobaleda-Siles, M., Guillamon A.P., Delpivo, C., Vázquez-Campos, S., Puentes V.F. 2016. Safer by design
649 strategies, *IOP Conf. Series: Journal of Physics: Conf. Series* 838 Nanosafe IOP Publishing.
650 012016 doi :10.1088/1742-6596/838/1/012016
- 651 Cooper R. G., and Edgett S. J. "Stage Gate Inc. Available: <https://www.stage-gate.com/>.
- 652 Cowley, S., Culvenor, J., & Knowles, J. 2000. Safe Design Project: review of literature and review of
653 initiatives of OHS authorities and other key players. Australian National Occupational Health
654 and Safety Commission. Brussels.

655 Dekkers, S., Wijnhoven, SWP., Braakhuis, H.M., Lya G.Soeteman-Hernandez L.G., Sips A.J.A.M.,
656 Tavernaro I., Kraegeloh, A., Noorlander, C.W. 2020. Safe-by-Design Part I: Proposal for
657 nanospecific safety aspects needed along the innovation process. *NanoImpact* (in press).

658 Directive 89/391/EEC of 12 June 1989 on the introduction of measures to encourage improvements
659 in the safety and health of workers at work. Brussels.

660 Directive 2001/95/EC of the European Parliament and of the Council of 3 December 2001 on general
661 product safety. Brussels.

662 Directive 2010/75/EU of the European Parliament and of the Council of 24 November 2010 on
663 industrial emissions. Brussels.

664 Donaldson, K., Murphy, F.A., Duffin, R., Poland, C.A. 2010. Asbestos, carbon nanotubes and the pleural
665 mesothelium: a review of the hypothesis regarding the role of long fibre retention in the
666 parietal pleura, inflammation and mesothelioma. Part. *Fibre Toxicol.* 7, 5

667 Duncan, T.V. 2015 Release of Engineered Nanomaterials from Polymer Nanocomposites: the Effect of
668 Matrix Degradation. *ACS Appl. Mater. Interfaces.* 7, 20–39.

669 Duncan, T.V., Pillai, K. 2015. Release of Engineered Nanomaterials from Polymer Nanocomposites:
670 Diffusion, Dissolution, and Desorption. *ACS Appl. Mater. Interfaces.* 7, 2–19.

671 EN 17058: 2018 Workplace exposure – Assessment of exposure by inhalation of nano-objects and
672 their aggregates and agglomerates Nanomaterial grouping: Existing approaches and future
673 recommendations.

674 Faure, B., Sæderup Lindeløv J., Wahlberg ,M., Adkins, N.J P., Bergström, L. 2010. Spray drying of TiO₂
675 nanoparticles into redispersible granules. *Powder Technology.* 203, 384–388

676 Geraci, C., Heidel, D., Sayes, C., Hodson, L., Schulte, P., Eastlake A., and Brenner, S., 2015. Perspectives
677 on the design of safer nanomaterials and manufacturing processes, *J Nanopart Res.* 17, 366

678 Giusti , A., Atluri,, R., Tsekovskad, R., Gajewicze. A., Apostolovad, M., Battistellif, C.L., Bleeker, E.A.J.,
679 Bossaf, C., Bouillar, J., Dusinska, M., Gómez-Fernández, P., Grafströmk, R., Gromelskie, M.,
680 Handzhiyskid, Y., Jacobsen, N.R., Jantunenm, P., Jensen, K.A., Agnieszka Mechm, A., Navas,
681 .JM., Nymarkk, P., .Oomeng, A., Puzyn, T., Rasmussen, K., Riebeling, C., Rodriguez-Llopis, I.,
682 Sabella, S., Riego Sintes, J., Suarez-Merino, B., Tanasescu, S., Wallin, S., Haase, A., Goedkoop,
683 M., Heijungs, R., Huijbregts, M.A.J., Schryver, A., Struijs, J., Zelm, R. 2019. Nanomaterial
684 grouping: Existing approaches and future recommendations. *NanoImpact.* 16, 100182

685 Goedkoop, M., Heijungs, R., Huijbregts, M., Schryver, A., Struijs, J., Zelm, R. 2008. ReCiPE 2008: A life
686 cycle impact assessment method which comprises harmonised category indicators at the
687 midpoint and the endpoint level.

688 Hansen, S. F., Baun, A. and Jensen, KA. 2011. NanoRiskCat – a conceptual decision support tool for
689 nanomaterials. Danish Ministry of the Environment. Environmental Project, No. 1372 2011
690

691 Hadrup, N., Sharma, A.K., Loeschner, K., 2018. Toxicity of silver ions, metallic silver, and silver
692 nanoparticle materials after in vivo dermal and mucosal surface exposure: A review. *Regul.*
693 *Toxicol. Pharmacol.* 98, 257-267

694 Hassan, M.M., Dylla, H., Mohammad, L.N., Rupnow, T. 2010. Evaluation of the durability of titanium
695 dioxide photocatalyst coating for concrete pavement,” *Construction and Building*
696 *Materials.* 24, 1456-1461

697 Hristozov, D.R., Zabeo, A., Foran, C., Isigonis, P., Critto, A., Marcomini, A., and Linkov, I.2014. A weight
698 of evidence approach for hazard screening of engineered nanomaterials. *Nanotoxicology.* 8,
699 72–87.

700 Höck J., Behra R., Bergamin L., Bourqui-Pittet M., Bosshard C., Epprecht T., Furrer V., Frey S., Gautschi
701 M., Hofmann H., Höhener K., Hungerbühler K., Knauer K., Krug H., Limbach L., Gehr P., Nowack
702 B., Riediker M., Schirmer K., Schmid K., Som C., Stark W., Suarez Merino B., Ulrich A., von Götz
703 N., Walser T., Wengert S., Wick P., Studer C.: Guidelines on the Precautionary Matrix for
704 Synthetic Nanomaterials. Federal Office of Public Health and Federal Office for the
705 Environment, Berne 2018, Version 3.1

706 Hjorth, R., van Hove, L., and Wickson, F., 2017. What can nanosafety learn from drug development?
707 The feasibility of “safety by design”, *Nanotoxicology*, 11, 305-312

708 Hsu, P.C., Liu, X., Liu, C., Xie, X., Lee, H.R., Welch, A.J., Zhao, T., Cui, Y. 2015. Personal Thermal
709 Management by Metallic Nanowire-Coated Textile. *Nano Lett.* 15, 365

710 ISO 2014. Nanotechnologies — Occupational risk management applied to engineered nanomaterials
711 — Part 2: Use of the control banding approach. ISO/TS 12901-2:2014

712 Jacobsen, N.R., Gómez P., Goñi F, García A., Hadrup N., Rodriguez-Llopis I., García E., Merino Sanchez
713 C., Trouiller B., Apostolova, M.D., Runden Pla, E., Dusinska, M., Gral, R. 2020. In vitro and in
714 vivo toxicity testing of industrial Carbon nanofibers. (in preparation)

715 Kalma, J., Merino, C., Fernandez-Cruz, M.L., Navas, J.M. (2019) Usefulness of fish cell lines for the initial
716 characterization of toxicity and cellular fate of graphene-related materials (carbon nanofibers
717 and graphene oxide). *Chemosphere.* 218, 347-358

718 Kraegeloh, A., Suarez-Merino B., Sluijters, T., Micheletti, C. 2018. Implementation of Safe-by-Design
719 for Nanomaterial Development and Safe Innovation: Why We Need a Comprehensive
720 Approach. *Nanomaterials.* 14;8

721 Kletz, T.A. 2003. Inherently Safer Design—Its Scope and Future. *Process Safety and Environmental*
722 *Protection.*81, 401-405

723 Kristensen, H.V., Hansen, S.V., Holm, G.R., 2010. Nanopartikler i arbejdsmiljøet: Viden og inspiration
724 om håndtering af nanomaterialer [Internet] Available from: [http:// nanosafet.i-](http://nanosafet.i-bar.dk/media/Nanopartikler_i_arbejdsmiljoet_samlet.pdf)
725 [bar.dk/media/Nanopartikler_i_arbejdsmiljoet_samlet.pdf](http://nanosafet.i-bar.dk/media/Nanopartikler_i_arbejdsmiljoet_samlet.pdf)

726 Lindeløv, J.S. and Wahlberg, M. 2011. Consolidating nanoparticles in micron-sized granules using spray
727 drying. *Journal of Physics: Conference Series.* 304. 012083.

728 Nanogenotox 2009 Deliverable 3: Final protocol for producing suitable MN exposure media. FP7 Grant
729 Agreement n° 2009 21 01

730 Maskrot, 2010. Method for the dry granulation of nanometric particles. Patent EP2648834, 2010

731 Midander, K., Julander, A., Kettelarij, J., Lidén, C. 2016. Testing in artificial sweat – Is less more?
732 Comparison of metal release in two different artificial sweat solutions. *Regulatory Toxicology*
733 *and Pharmacology.* 81, 381-386

734 NIOSH 2011 Prevention through design. Planl for the National Initiative. Deparemnt of helath adn
735 Human Services. Centers for Disease Control and Prevention National Institute for
736 Occupational Safety and Health Publication No. 2011–121

737 NIOSH 2012 General Safe Practices for Working with Engineered Nanomaterials in Research
738 Laboratories U.S. Department of Health and Human Services, Centers for Disease Control and
739 Prevention, National Institute for Occupational Safety and Health NIOSH (DHHS (NIOSH)
740 Publication No. 2012–147

741 NIOSH 2013 Current strategies for engineering controls in nanomaterial production and downstream
742 handling processes. Cincinnati, OH: U.S. Department of Health and Human Services, Centers

743 for Disease Control and Prevention, National Institute for Occupational Safety and Health,
744 DHHS (NIOSH) Publication No. 2014–102.

745 NRC 2011 Prudent practices in the laboratory: handling and management of chemical hazards,
746 updated version. Washington, DC: The National Academic Press, National Research Council

747 Pennington, D. W., Potting, J., Finnveden, G., Lindeijer, E., Jolliet, O., Rydberg, T., Rebitzer, G. 2004.
748 "Life cycle assessment Part 2: Current impact assessment practice." Environment
749 International. 30, 721-739.

750

751 Peetla, C., Labhasetwar, V. 2009. Effect of molecular structure of cationic surfactants on biophysical
752 interactions of surfactant-modified nanoparticles with a model membrane and cellular
753 uptake, Langmuir. 25, 2369–2377

754 Peetla, V., Jin, S., Weimer, J., Elegbede, A., Labhasetwar, V. 2014. Biomechanics and thermodynamics
755 of nanoparticle interactions with plasma and endosomal membrane lipids in cellular uptake
756 and endosomal escape. Langmuir. 30, 7522–7532.

757 Perrin, J.F. and Oudart, Y. 2017. Production method incorporating particles containing silicon. Patent
758 FR3075826B1, 2017

759 Poland, C.A, Duffin, R., Kinloch, I., Maynard, A., Wallace, W.A., Seaton, A., Stone, V., Brown, S., Macnee,
760 W., Donaldson, K. 2008 Carbon nanotubes introduced into the abdominal cavity of mice show
761 asbestos-like pathogenicity in a pilot study. Nature Nanotechnology. 7, 423-8

762 ProSafe, 2017. ProSafe White Paper. Towards a more effective and efficient governance and
763 regulation of nanomaterials. ProSafe Project Office

764 Raghupathy, B.P.C. and Binner, J.G.P. 2012. Spray freeze drying of YSZ (Yttria stabilised Zirconia)
765 nanopowder. J Nanopart Res. 14, 921

766 Regulation (EC) No 1935/2004 of the European Parliament and of the Council of 27 October 2004 on
767 materials and articles intended to come into contact with food and repealing Directives
768 80/590/EEC and 89/109/EEC. Brussels.

769 Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006
770 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH).
771 Brussels.

772 Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008
773 on classification, labelling and packaging of substances and mixtures. Brussels.

774 Regulation (EC) No 1333/2008/EC of the European Parliament and of the Council of 16 December
775 2008 on food additives. Brussels.

776 Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009
777 on cosmetic products. Brussels.

778 Regulation EU No 528/2012 of the European Parliament and of the Council of the concerning the
779 making available on the market and use of biocidal products. Brussels.

780 Regulation (EC) No. 649/2012 of the European Parliament and of the Council of 4 July 2012 concerning
781 the export and import of hazardous chemicals

782 Regulation (EC) No 2015/2283 of the European Parliament and of the Council of 25 November 2015
783 on novel foods

784 Regulation (EC) No 2020/561 of the European Parliament and of the Council of 23 April 2020 amending
785 Regulation (EU) 2017/745 on medical devices, as regards the dates of application of certain of
786 its provisions.

787 Salieri, B. and Hischier, R. 2020 Integration framework to ensure safe and sustainable nanomaterials
788 and nano-enabled products (In preparation for submission to NanoImpact).

789 Sánchez Jiménez, A., Puellas, R., Perez-Fernandez M., Gómez, P., Barruetabeña, L., Jacobsen, N.R.,
790 Suarez-Merino, B., Micheletti C., Manier N., Trouiller, B., Navas, J.M., Salieri, B., Hischier,
791 R., Handzhiyski Y., Apostolova, A.D., Hadrup, N., Bouillard, J., Oudart, Y., Merino, C., Garcia,
792 E., Liguori, B., Rose, J., Maison, A., Galea K.S., Kelly, S., Shandilya, N., Goede, H., Gomez-
793 Cordon, J., Jensen, K.A., van Tongeren⁰ M., Rodríguez Llopis, I. 2020 Safe by Design
794 guidelines for the nanotechnology industry. (In preparation for submission to NanoImpact)

795 SCCS/1611/19. Guidance on the Safety Assessment of Nanomaterials in Cosmetics. Scientific
796 Committee on Consumer Safety

797 Sengupta, B., Gregory, W.E., Zhu, J., Dasetty, S., Karakaya, M., Brown, J. M., Rao, A. M., Barrows, J. K.,
798 Sarupria, S., Podila, R. 2015 Influence of carbon nanomaterial defects on the formation of
799 protein corona. RSC Adv. 5, 82395–82402

800 Shi, X., von Dem Bussche, A., Hurt, R.H., Kane, A.B., Gao, H. 2011. Cell entry of one-dimensional
801 nanomaterials occurs by tip recognition and rotation. Nature nanotechnology, 6:714–
802 719. SCENIHR, 2015 Guidance on the Determination of Potential Health Effects of
803 Nanomaterials Used in Medical Devices. Scientific Committee on Emerging and Newly
804 Identified Health Risks. European Commission. Directorate of Public Health.

805 Soeteman-Hernandez, L., Apostolova, M., Braakhuis, H.M., Dekkers, S., Grafström, R. C., Groenewold,
806 M., et al. 2019 Safe Innovation Approach: Towards an agile system for dealing with
807 innovations. 20, 100548

808 Sotiriou, G.A, Watson, C., Murdaugh, K.M., Darrah, T.H., Pyrgiotakis, G., Elder, A., Brain, J.D.,
809 Demokritou, P. 2014. Engineering safer-by-design silica-coated ZnO nanorods with reduced
810 DNA damage potential. Environ. Sci. Nano. 1, 144–153

811 Suarez Merino, B., Rodríguez-Llopis, I., Gómez-Fernández, P., Haase, A., Giusti, A., Jacobsen, N.R.,
812 Jensen, K.A., Dusinska, M., Rundén-Pran, E., Mariussen, E., Sandström, J., Aicher, L., Gromelski,
813 M., Puzyn, T., Carnovale, C., Balusamy, B., Apostolova, M., De Angelis, I., Barone, F., Battistelli
814 C, Bossa C, Zijno, A., Giuliani, A, Grall, R., Tanasescu, S. 2018. NanoReg2 grouping case studies
815 Human tox. Presented at the NanoReg2, OCED, Gracious joint meeting on the 12-13 September
816 2018 in Paris. <http://www.nanoreg2.eu/oecd-joint-meeting-sept-12-13>

817 Tsai, S.J., Hofmann, M., Hallock, M., Ada, E., Kong, J., Ellenbecker, M. 2009 Characterization and
818 Evaluation of Nanoparticle Release during the Synthesis of Single-Walled and Multiwalled
819 Carbon Nanotubes by Chemical Vapor Deposition. Environ. Sci. Technol. 15: 6017–6023

820 Turkevich, L.A., Dastidar, G., Hachmeister, Z., Lim, M. 2015. Potential explosion hazard of
821 carbonaceous nanoparticles: Explosion parameters of selected materials, Journal of Hazardous
822 Materials. 295, 97–103.

823 Van Duuren-Stuurman, B., Vink, S.R., Verbist, K.J., Heussen, H.G., Brouwer, D.H., Kroese, D.E., Van
824 Niftrik, M.F., Tielemans, E., Fransman, W. 2012. Stoffenmanager Nano version 1.0: a web-
825 based tool for risk prioritization of airborne manufactured nano objects. Ann Occup. Hyg. 56,
826 525-41

827 Vignes, A., Krietsch, A., Dufaud, O., Santandréa, A., Perrin, L., Bouillard, J. 2019. Course of explosion
828 behaviour of metallic powders – From micron to nanosize, Journal of Hazardous Materials.
829 379, 120767.

830 Vorbau, M., Hillemann, L., Stintz, M., 2009. Method for the characterization of the abrasion induced
831 nanoparticle release into air from surface coatings. Journal of Aerosol Science .40, 209-217.

832

833 Wassim, A., Degobert, G., Stainmesse, S., Hatem, F. 2006. Freeze-drying of nanoparticles: Formulation,
834 process and storage considerations. *Advanced Drug Delivery Reviews*. 58, 1688–1713

835 Wu, H.C., Ou, H.J., Hsiao, H.C., Shih, T.S. 2010. Explosion characteristics of aluminum nanopowders.
836 *Aerosol and Air Quality Research*. 10, 38–42.